Advanced Life Sciences Holdings, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs in the areas of infectious disease, inflammation, and oncology. It has an exclusive worldwide license from Abbott Laboratories to develop and commercialize cethromycin, a ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections. The company also develops ALS-886, a therapeutic in preclinical development for the treatment of inflammation-related tissue damage, including tissue damage associated with acute respiratory distress syndrome; and ALS-357, a compound that has shown evidence of...